Truist Securities has maintained its Buy rating and $570.00 price target for Intuitive Surgical (NASDAQ: NASDAQ:ISRG).
The firm's analysis highlighted the company's third-quarter revenue and earnings per share (EPS) growth, which outpaced expectations. Intuitive Surgical saw a significant beat in U.S. system sales, including 110 of its Da Vinci model 5 systems, surpassing the estimated 78 units.
The quarter also experienced a stronger-than-anticipated increase in procedures, growing at 18% year-over-year compared to the consensus estimate of approximately 17%. This growth was partly attributed to an additional sales day in the quarter.
The margin outperformance contributed to a 26% year-over-year rise in EPS. The early success of the Da Vinci model 5 during its 'soft launch' phase was particularly noted as a positive indicator for the company's future performance. Truist Securities expressed increased confidence in the potential for estimate increases and accelerated growth into 2025, when a full launch of the new system is planned.
Intuitive Surgical's performance has cemented its status as a preferred large-cap stock within the medical technology sector, according to Truist Securities. The firm anticipates that Intuitive Surgical will continue to deliver mid-to-high teens revenue and EPS growth.
The company is also expected to sustain its substantial lead in the market for robotic surgical systems, which is still largely untapped and presents a significant opportunity for growth.
In other recent news, Intuitive Surgical has seen a series of significant developments. The medical technology company reported strong third-quarter results for 2024, with revenues of $2.038 billion, marking a 16.9% year-over-year increase, and an adjusted earnings per share (EPS) of $1.84.
These figures exceeded both BTIG's and consensus estimates. Intuitive Surgical's system sales and procedure volumes also surpassed Street expectations, with the latter showing an 18% year-over-year growth.
The company is expected to continue its growth trajectory, especially with its Da Vinci 5 (Dv5) surgical systems, as it gains regulatory approvals to enter new markets. Additionally, various firms, including Evercore ISI, Baird, Wells Fargo (NYSE:WFC), BTIG, and RBC Capital Markets, have adjusted the company's stock target and ratings.
Intuitive Surgical has updated its guidance, now forecasting procedure growth of 16%-17% and a reduction in its operating expense growth to 10%-12%.
InvestingPro Insights
Intuitive Surgical's strong performance highlighted by Truist Securities is further supported by recent InvestingPro data. The company's market capitalization stands at an impressive $168.4 billion, reflecting its dominant position in the robotic surgical systems market. Intuitive Surgical's revenue growth of 13.62% over the last twelve months aligns with the analyst's positive outlook on the company's growth trajectory.
InvestingPro Tips indicate that Intuitive Surgical is trading near its 52-week high, with a substantial price uptick of 27.13% over the last six months. This momentum is consistent with the company's strong quarterly results and the market's enthusiasm for the Da Vinci model 5 system. Additionally, the company's high return over the last year, with a one-year price total return of 71.94%, underscores its strong market performance.
It's worth noting that Intuitive Surgical is trading at a high P/E ratio of 79.71, which may reflect investor expectations for continued growth. The company's robust financial health is evident in its liquid assets exceeding short-term obligations, providing a solid foundation for future investments and expansions.
For investors seeking a deeper understanding of Intuitive Surgical's potential, InvestingPro offers 15 additional tips, providing a comprehensive analysis of the company's financial position and market outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.